Coverage Expanded for CellCept, Rinvoq, and Cedaconda
Patient access to essential medical therapies has been broadened through the extension of coverage for CELLCEPT (mycophénolate mofétil), RINVOQ (upadacitinib) 15 mg, and CEDACONDA (isoflurane).

This update to reimbursement guidelines ensures that these specific medications are more readily available to patients who require them for their treatment plans. By extending coverage, health systems can help reduce the financial barriers that often hinder access to specialized pharmaceutical care.
Ensuring the availability of critical medications is a vital component of public health, as it supports better adherence to treatment regimens and improves overall patient outcomes.